



Food and Drug Administration  
Rockville MD 20857

Re: Gynecare Intergel  
Docket No. 02E-0150

The Honorable James E. Rogan  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office  
Box Pat. Ext.  
P.O. Box 2327  
Arlington, VA 22202

FEB 21 2002

Dear Director Rogan:

This is in regard to the application for patent term extension for U.S. Patent No. 5,532,221, filed by Lifecore Medical, Inc., under 35 U.S.C. § 156 *et seq.* We have reviewed the dates contained in the application and have determined the regulatory review period for Gynecare Intergel, the medical device claimed by the patent.

The total length of the regulatory review period for Gynecare Intergel is 2,438 days. Of this time, 1,453 days occurred during the testing phase and 985 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date a clinical investigation on humans involving this device was begun: March 17, 1995.

FDA has verified the applicant's claim that the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act for human tests to begin became effective on March 17, 1995.

2. The date the application was initially submitted with respect to the device under section 515 of the Federal Food, Drug, and Cosmetic Act: March 8, 1999.

The applicant claims March 5, 1999, as the date the premarket approval application (PMA) for Gynecare Intergel [PMA P990015] was initially submitted. However, FDA records indicate that PMA P990015 was submitted on March 8, 1999.


3. The date the application was approved: November 16, 2001.

FDA has verified the applicant's claim that PMA P990015 was approved on November 16, 2001.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Jane A. Axelrad". The signature is fluid and cursive, with the first name "Jane" being the most prominent.

Jane A. Axelrad

Associate Director for Policy

Center for Drug Evaluation and Research

cc: Walter J. Steinkraus  
Vida, Arrett & Steinkraus, P.A.  
6109 Blue Circle Drive  
Minnetonka, MN 55391